The abstract does not explicitly state a question, but it investigates the role of cellular senescence in aging and chronic diseases and the potential for therapeutic intervention.
Fisetin Senolytic Capsules (EBioMedicine 2017, PMID 28416161) — senolytic agents, which target SCAPs and induce senescent cell apoptosis, show promise in pre-clinical models for alleviating senescence-related conditions and are being translated into clinical interventions. No numeric effect size is reported for Fisetin Senolytic Capsules in the source abstract.
Source: EBioMedicine 2017, PMID 28416161 ↗ · Research map · How Magellan grades evidence · evidence confidence: low
EBioMedicine · 2017 · PMID 28416161 · DOI 10.1016/j.ebiom.2017.04.013
Targeting senescent cells with senolytic drugs shows promise for treating age-related diseases and chronic conditions by removing harmful cells.
The question
The abstract does not explicitly state a question, but it investigates the role of cellular senescence in aging and chronic diseases and the potential for therapeutic intervention.
What they tested
The abstract implies a hypothesis that targeting senescent cells by inhibiting their pro-survival pathways (SCAPs) could alleviate senescence-associated conditions.
How they did it
The authors used a hypothesis-driven approach to discover Senescent Cell Anti-apoptotic Pathways (SCAPs) and subsequently identified senolytic agents based on these pathways. These agents were then tested in pre-clinical models.
What they found
Senescent cells accumulate with aging and in chronic diseases, contributing to inflammation, metabolic dysregulation, and other pathologies through the SASP. Delaying or reducing senescent cell burden is linked to improved outcomes. The discovery of SCAPs led to the identification of senolytic agents that alleviate multiple senescence-related phenotypes in pre-clinical models.
What it means
Cellular senescence plays a significant role in aging and chronic diseases. Senolytic agents, which target SCAPs and induce senescent cell apoptosis, show promise in pre-clinical models for alleviating senescence-related conditions and are being translated into clinical interventions.
Limitations
The abstract does not explicitly state limitations of the study. It mentions that senolytic agents are 'beginning the process of being translated into clinical interventions,' implying that human clinical data is still emerging or not yet available.
Where the published abstract does not list limitations, we say so rather than inventing them. Read the full paper on PubMed before drawing conclusions.
The paper at a glance
| Title | Cellular Senescence: A Translational Perspective |
|---|---|
| Journal | EBioMedicine |
| Year | 2017 |
| PMID | 28416161 ↗ |
| DOI | 10.1016/j.ebiom.2017.04.013 ↗ |
| Topic | Senescence, senolytics & the hallmarks of aging |
Read the source: PubMed record (authors, abstract, full citation) ↗ · Publisher via doi.org ↗
Where Magellan uses this paper
This citation sits behind the evidence grade on the pages below. Grades are set from the research and are independent of affiliate commissions.
Fisetin Senolytic Capsules
Because senescent cells accumulate with age and contribute to frailty, vascular dysfunction, inflammation, and multiple age-related diseases, selectively clearing them is a leading longevity strategy.
Fisetin is a naturally occurring flavonol (a plant polyphenol) found in strawberries, apples…
Research describes the compound or intervention studied. It is not a claim about any specific product.
Molecules & mechanisms in this paper
Each of these is named in the paper’s own words above. Open the monograph for the full mechanism and its other citations.
Cite this page
These citations point at this summary. To cite the original paper with its full author list, use the PubMed record or doi.org.
Magellan Longevity. (2026). The abstract does not explicitly state a question, but it investigates the role of cellular senescence in aging and chronic diseases and the potential for therapeutic intervention. [Plain-English summary of EBioMedicine 2017, PMID 28416161, DOI 10.1016/j.ebiom.2017.04.013]. Magellan Longevity. https://magellanlongevity.com/study/d28416161.html@misc{magellan_d28416161,
title = {The abstract does not explicitly state a question, but it investigates the role of cellular senescence in aging and chronic diseases and the potential for therapeutic intervention.},
author = {{Magellan Longevity}},
year = {2026},
howpublished = {\url{https://magellanlongevity.com/study/d28416161.html}},
note = {Plain-English summary of PubMed PMID 28416161; DOI 10.1016/j.ebiom.2017.04.013; EBioMedicine 2017. Reviewed by Gabriel Radu, DO},
urldate = {2026-08-11}
}https://magellanlongevity.com/study/d28416161.htmlRelated studies in the Magellan library
- Fisetin is a senotherapeutic that extends health and lifespanEBioMedicine · 2018 · PMID 30279143
- Senolytic drugs: from discovery to translationJ Intern Med · 2020 · PMID 32686219
- Hyperbaric oxygen therapy increases telomere length and decreases immunosenescence in isolated…Aging (Albany NY) · 2020 · PMID 33206062
- Does taurine deficiency contribute to aging, and can taurine supplementation improve health…Science · 2023 · PMID 37289866
- Insights into the therapeutic strategies for aging and aging-associated diseasesSignal Transduction and Targeted Therapy · 2026 · PMID 42225652
- Higher spermidine intake is linked to lower mortalityThe American Journal of Clinical Nutrition · 2018 · PMID 29955838
All 8 Magellan summaries on senescence, senolytics & the hallmarks of aging →
Prefer the interactive version? Open this summary in the Magellan app → · Browse all 314 study summaries →